Amini: The majority of these patients — except at this time stage 1 — will need systemic therapy as part of their therapy, whether it is in the locally advanced resectable or unresectable case or ...

Amini: From a radiation standpoint, this has changed the landscape of our field. A large proportion of my practice is stage IV disease, where patients who are on these excellent systemic therapies are ...

Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond ...

The biopsy came back positive. It’s lung cancer.” Countless people in our community hear these words no one ever expects.

A previous study showed a confirmed objective response rate of 42.9% with the KRAS G12C inhibitor adagrasib in previously treated patients with NSCLC. In this phase III trial, median progression-free ...

While smoking remains the leading risk factor, other contributors include secondhand smoke, air pollution, radon exposure and ...

CHICAGO -- SGLT2 inhibitor use was linked to reduced progression of in-situ pulmonary adenocarcinoma, an observational study showed. Nodule growth over the median 28 months of follow-up was 62% less ...

According to the American Lung Association, the national five-year lung cancer survival rate is about 29.7 percent. The ...

The robot is designed to help doctors detect lung cancer at earlier stages.